Navigation Links
MarginProbe® Pivotal Study Presented at San Antonio Breast Cancer Symposium

FRAMINGHAM, Mass., Dec. 7, 2011 /PRNewswire/ -- Data from the MarginProbe pivotal study were presented today during the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.  The results were presented by Dr. Freya Schnabel, Director of Breast Surgery, NYU Langone Medical Center, New York University, New York, New York.  In a 596 patient randomized study, adjunctive use of MarginProbe significantly improved surgical outcomes by improving surgeons' ability to identify and immediately resect positive margins, reducing the number of patients requiring re-excision by 57%.

"Second surgeries are difficult on the patient, both physically and emotionally," said Dr. Schnabel.  "On average, about 30% of patients will require more than one surgery to completely remove the cancer.  In our study, we saw a similar rate in the control arm, but by using MarginProbe, we were able to cut that in half.  This represents a substantial improvement in patient care and quality, as well as reducing costs.  I am very excited to see the device available to surgeons in the US."

"We are very pleased with the response of the surgeon community to these data.  Every lumpectomy surgery has the need for improved ability to achieve cancer-free margins and we believe these data present substantial evidence supporting the approval and widespread adoption of the MarginProbe System," said Dan Levangie, CEO of Dune Medical Devices.

About the MarginProbe System
The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer.  The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure.  The MarginProbe System is Dune's first commercial product and is commercially available in Europe.  The MarginProbe device is an investigational device in the U.S.

About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology.  Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. 

Dune Medical Devices is a privately held company financed by Apax Partners since 2004.  It has offices in the U.S., Israel, Germany and Switzerland.  For more information, please visit   

Michael Graffeo
Dune Medical Devices
(508) 620-2782

SOURCE Dune Medical Devices
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
2. Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
3. ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514
4. PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.
5. EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System
6. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
7. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
8. First Patient Enrolled in SARcode Biosciences Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
9. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
10. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
11. Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
Post Your Comments:
(Date:11/30/2015)... 2015 2014RestatedChange%Turnover 545,575 , 518,852 , 5.2 Cord Blood ... , 9.8 Hospital Management Service Income , ... Medical Insurance Administration Service Income , 2,780 , ... , 89,645 , 94,580 , ... 2,917 , (3.3) Gross Profit 395,857 , ...
(Date:11/30/2015)...  PTS Diagnostics, the U.S.-based manufacturer of point-of-care biometric ... ® systems, and PTS Detect™ cotinine systems, has ... will propel the company into the mHealth market. ... . The technology is a system that interfaces ... and tablets, and uses test strip technology already developed ...
(Date:11/30/2015)... Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), today announced that ... at on December 3, 2015. TIME: 3:15p.m. ... 3:15p.m. ET LINK: --> ... --> --> ... investors are invited to ask the company questions in real-time ...
Breaking Medicine Technology:
(Date:11/30/2015)... York (PRWEB) , ... November 30, 2015 , ... In ... of his role as a top ophthalmologist on Long Island’s east end. During the ... teaching, innovations in surgery and treatment of glaucoma and cataracts, and how a visit ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its ... specializing in independent living, assisted living and all other retirement options. Support for ... awareness and research remains a top priority. , So it’s no surprise ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of the leading plastic surgery practices in Florida, is proud to announce that ... for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... 30, 2015 , ... Vasont Systems, a top component content ... extension unites with Syncro Soft’s latest software update, oXygen XML editor Version 17.1. ... the latest release of oXygen® XML editor and the Vasont® CCMS. , ...
Breaking Medicine News(10 mins):